Autolus Therapeutics plc (NASDAQ:AUTL) Shares Sold by Walleye Capital LLC

Walleye Capital LLC lowered its stake in shares of Autolus Therapeutics plc (NASDAQ:AUTL) by 10.6% during the third quarter, Holdings Channel reports. The firm owned 1,062,393 shares of the company’s stock after selling 126,100 shares during the period. Walleye Capital LLC’s holdings in Autolus Therapeutics were worth $3,856,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in AUTL. ProShare Advisors LLC acquired a new stake in Autolus Therapeutics during the 2nd quarter worth $43,000. Daiwa Securities Group Inc. increased its position in shares of Autolus Therapeutics by 2,659.7% during the second quarter. Daiwa Securities Group Inc. now owns 15,868 shares of the company’s stock worth $55,000 after purchasing an additional 15,293 shares in the last quarter. B. Riley Wealth Advisors Inc. purchased a new stake in shares of Autolus Therapeutics in the 1st quarter valued at about $108,000. Herbst Group LLC acquired a new stake in shares of Autolus Therapeutics in the 3rd quarter valued at about $91,000. Finally, China Universal Asset Management Co. Ltd. grew its stake in Autolus Therapeutics by 63.8% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 38,393 shares of the company’s stock worth $139,000 after buying an additional 14,959 shares during the last quarter. Institutional investors and hedge funds own 72.83% of the company’s stock.

Autolus Therapeutics Trading Down 1.8 %

Autolus Therapeutics stock opened at $3.26 on Tuesday. The stock has a market capitalization of $867.45 million, a price-to-earnings ratio of -2.74 and a beta of 2.04. The stock has a 50 day moving average of $3.72 and a two-hundred day moving average of $3.91. Autolus Therapeutics plc has a twelve month low of $2.69 and a twelve month high of $7.45.

Autolus Therapeutics (NASDAQ:AUTL) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.31) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.10). During the same quarter in the previous year, the firm posted ($0.26) EPS. Equities analysts predict that Autolus Therapeutics plc will post -0.94 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on the company. The Goldman Sachs Group upgraded Autolus Therapeutics from a “neutral” rating to a “buy” rating and boosted their price objective for the company from $7.00 to $7.60 in a research note on Monday, November 18th. Needham & Company LLC reaffirmed a “buy” rating and issued a $9.00 target price on shares of Autolus Therapeutics in a report on Monday, November 11th. Finally, Redburn Atlantic upgraded shares of Autolus Therapeutics from a “neutral” rating to a “buy” rating and set a $13.00 price target for the company in a research note on Friday, November 15th. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat, Autolus Therapeutics has an average rating of “Buy” and an average target price of $10.15.

Autolus Therapeutics Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.